Background: Long-term oxygen therapy (LTOT) is the cornerstone mode of treatment in patients with chronic obstructive pulmonary disease (COPD). Objectives: The present study aims to investigate the effect of two oxygen sources (concentrator and liquid oxygen) on quality of life, exercise tolerance and compliance to LTOT in patients with COPD. Methods: The survey included 104 patients with COPD (31 on concentrator treatment and 73 on liquid oxygen). Patients were subjected to pulse oximetry, basic spirometry, measurement of health-related quality of life by the St. George’s Hospital respiratory questionnaire instrument and assessment of dyspnoea severity by the modified Borg category scale. Exercise tolerance was evaluated by the SaO2 value after 3 min of walking. SaO2 was measured before and after treatment with each device. Compliance with therapy was defined by the daily duration of oxygen use. Results: The two LTOT groups did not differ significantly concerning pulmonary function tests (p = 0.49 for FEV1, 0.98 for FVC, 0.15 for FEV1/FVC% and 0.38 for FEF50%), SaO2 before (p = 0.28) and after (p = 0.80) O2 treatment and after the 3-min walking trial (p = 0.47), and St. George’s Hospital respiratory questionnaire score (p = 0.45). The liquid oxygen group was less dyspnoeic before treatment (p = 0.02), but this difference disappeared after treatment (p = 0.95). A highly significant difference (p < 0.001) was noted concerning the daily oxygen use. Complete compliance to LTOT (≧15 h/day) was observed in 12.9 and 42.5%, respectively (p < 0.005). Noise disturbance was noted only in the concentrator group (80%). Conclusions: We conclude that stationary liquid oxygen seems to be a satisfactory alternative mode for LTOT treatment in COPD patients, with higher patient compliance to therapy in comparison with concentrators.

1.
Nocturnal Oxygen Therapy Trial Group: Continuous or nocturnal oxygen therapy in hypoxaemic chronic obstructive lung disease: a clinical trial. Ann Intern Med 1980;93:391–398.
2.
Medical Research Council Working Party: Long-term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1981;i:681–686.
3.
Petty TL: Controversial indications for long-term respiratory care: long-term oxygen therapy. Monaldi Arch Chest Dis 1999;54:58–60.
4.
Pauwels RA, Buist AS, Calverley PMA, Jenkins CR, Hurd SS, Gold Scientific Committee: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary. Am J Respir Crit Care Med 2001;163:1256–1276.
5.
Celli BR, MacNee W, ATS/ERS Task Force: Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932–946.
6.
Zielinski J, Tobiasz M, Hawrylkiewicz I, Sliwinski P, Palasiewicz G: Effects of long-term oxygen therapy on pulmonary hemodynamics in COPD patients: a 6-year prospective study. Chest 1998;113:65–70.
7.
Oswald-Mammosser M, Weitznblum E, Quoix E, Moser G, Chaouat A, Charpentier C, Kessler R: Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure. Chest 1995;107:1193–1198.
8.
Petty TL, Bliss PL: Ambulatory oxygen therapy, exercise, and survival with advanced chronic obstructive pulmonary disease (the Nocturnal Oxygen Therapy Trial revisited). Respir Care 2000;45:204–211.
9.
Keller RR: Long-term oxygen therapy: advances and perspectives in technical devices. Monaldi Arch Chest Dis 1999;54:75–78.
10.
Ström K, Herala M, Boman G, Gustavil A: Assessment of two oxygen treatment alternatives in the home. Int J Technol Assess Health Care 1990;6:489–497.
11.
Howard P, de Haller R: Working Group on Oxygen Therapy of IUALD. Domiciliary oxygen – by liquid or concentrator? Eur Respir J 1991;4:1284–1287.
12.
Andersson A, Ström K, Brodin H, Alton M, Boman G, Jakobsson P, Lindberg A, Uddenfeldt M, Walter H, Levin LA: Domiciliary liquid oxygen versus concentrator treatment in chronic hypoxaemia: a cost-utility analysis. Eur Respir J 1998;12:1284–1289.
13.
Pepin JL, Barjhoux CE, Deschaux C, Brambilla C: Long-term oxygen therapy at home. Compliance with medical prescription and effective use of therapy. ANTADIR Working Group on Oxygen Therapy. Association Nationale de Traitement à Domicile des Insuffisants Respiratoires. Chest 1996;109:1144–1150.
14.
Heaton RK, Grant I, McSweeny AJ, Adams KM, Petty TL: Psychologic effects of continuous and nocturnal oxygen therapy in hypoxemic chronic obstructive pulmonary disease. Arch Intern Med 1983;143:1941–1947.
15.
Okubadejo AA, Paul EA, Jones PW, Wedzicha JA: Does long-term oxygen therapy affect quality of life in patients with chronic obstructive pulmonary disease and severe hypoxaemia? Eur Respir J 1996;9:2335–2339.
16.
Crockett AJ, Cranston JM, Moss JR, Alpers JH: Effects of long-term oxygen therapy on quality of life and survival in chronic airflow limitation. Monaldi Arch Chest Dis 1999;54:193–196.
17.
Eaton T, Lewis C, Young P, Kennedy Y, Garrett JE, Kolbe J: Long-term oxygen therapy improves health-related quality of life. Respir Med 2004;98:285–293.
18.
Morrison D, Skwarski K, MacNee W: Review of the prescription of domiciliary long-term oxygen therapy in Scotland. Thorax 1995;50:1103–1105.
19.
Ringbaek T, Lange P, Viskum K: Compliance with LTOT and consumption of mobile oxygen. Respir Med 1999;93:333–337.
20.
Granados A, Escarrabill J, Borras JM, Rodriguez-Roisin R: The importance of process variables analysis in the assessment of long-term oxygen therapy by concentrator. Respir Med 1997;91:89–93.
21.
Kampelmacher MJ, Van Kesteren RG, Alsbach GP, Melissant CF, Wynne HJ, Douze JM, Lammers JW: Prescription and usage of long-term oxygen therapy in patients with chronic obstructive pulmonary disease in The Netherlands. Respir Med 1999;93:46–51.
22.
Hoang Thi TH, Guillemin F, Cornette A, Poli JM, Briançon S: Health-related quality of life in long-term oxygen treated chronic obstructive pulmonary disease patients. Lung 1997;175:63–71.
23.
Schaanning J, Ström K, Boe J: Do patients using long-term liquid oxygen differ from those on traditional treatment with oxygen concentrators and/or compressed gas cylinders? A comparison of two national registers. Respir Med 1998;92:84–87.
24.
Tzanakis N, Bouros D, Mamatzakis P, Samiou M, Siafakas NM: Long-term oxygen therapy on the island of Crete, Greece. Monaldi Arch Chest Dis 1998;53:533–536.
25.
Katsenos S, Froudarakis ME, Charisis A, Vassiliou MP, Constantopoulos SH: Long-term oxygen therapy in Ioannina. Respiration 2004;71:619–624.
26.
Wilson RC, Jones PW: Long-term reproducibility of Borg scale estimates for breathlessness during exercise. Clin Sci 1991;80:309–312.
27.
Iriberri M, Galdiz JB, Gorostiza A, Ansola P, Jaca C: Comparison of the distances covered during 3 and 6 min walking test. Respir Med 2002;96:812–816.
28.
Quanjer P, Tammeling G, Cotes J, Pedersen OF, Peslin R, Yernault JC: Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J 1993;6(suppl 16):5–40.
29.
Jones PW, Quirk FH, Baveystock CM, Littlejohns P: A self-complete measure for chronic airflow limitation: the St George’s respiratory questionnaire. Am Rev Respir Dis 1992;145:1321–1327.
30.
Quirk FH, Baveystock CM, Wilson RC, Jones PW: Influence of demographic and disease related factors on the degree of distress associated with symptoms and restrictions on daily living due to asthma in six countries. Eur Respir J 1991;4:167–171.
31.
Tzanakis N, Samiou M, Lambiri I, Antoniou K, Siafakas N, Bouros D: Evaluation of health-related quality of life and dyspnea scales in patients with idiopathic pulmonary fibrosis. Correlation with pulmonary function tests. Eur J Intern Med 2005;16:105–112.
32.
Buyse B, Demedts M: Long-term oxygen therapy with concentrators and liquid oxygen. Acta Clin Belg 1995;50:149–157.
33.
West GA, Primeau P: Nonmedical hazards of long-term oxygen therapy. Respir Care 1983;28:906–912.
34.
Janssens JP, Rochat T, Frey JG, Dousse N, Pichard C, Tschopp JM: Health-related quality of life in patients under long-term oxygen therapy: a home-based descriptive study. Respir Med 1997;91:592–602.
35.
Lacasse Y, Lecours R, Pelletier C, Bégin R, Maltais F: Randomised trial of ambulatory oxygen in oxygen-dependent COPD. Eur Respir J 2005;25:1032–1038.
36.
Lahdensuo A, Ojanen M, Ahonen A, Laitinen J, Poppius H, Salorinne Y, Tammivaara R, Tukiainen P, Venho K, Vilkka V: Psychosocial effects of continuous oxygen therapy in hypoxaemic chronic obstructive pulmonary disease patients. Eur Respir J 1989;2:977–980.
37.
Guillemin F, Bombardier C, Beaton D: Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines. J Clin Epidemiol 1993;46:1417–1432.
38.
Peckham DG, McGibbon K, Tonkinson J, Plimbley G, Pantin C: Improvement in patient compliance with long-term oxygen therapy following formal assessment with training. Respir Med 1998;92:1203–1206.
39.
Kampelmacher MJ, Van Kesteren RG, Alsbach GP, Melissant CF, Wynne HJ, Douze JM, Lammers JW: Characteristics and complaints of patients prescribed long-term oxygen therapy in The Netherlands. Respir Med 1998;92:70–75.
40.
Zielinski J, Sliwinski P: Indications for and methods of long-term oxygen therapy (LTOT). Eur Respir Rev 1991;1:536–540.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.